

1 **Title:** Association of Baseline Cerebrovascular Reactivity and Longitudinal Development of
2 Enlarged Perivascular Spaces in the Basal Ganglia

3 **Short Title:** Baseline CVR and longitudinal ePVS development

4 **Authors:** T.J. Libecap^{1,2}, Christopher E. Bauer², Valentinos Zachariou², Colleen A. Pappas²,
5 Flavius D. Raslau³, Peiyong Liu⁴, Hanzhang Lu⁵, Brian T. Gold^{2,3,6,7}

6 ¹ MD/PhD Program, University of Kentucky College of Medicine, Lexington, Kentucky, USA

7 ² Department of Neuroscience, University of Kentucky College of Medicine, Lexington,
8 Kentucky, USA

9 ³ Department of Radiology, University of Kentucky College of Medicine, Lexington, Kentucky,
10 USA

11 ⁴ Department of Radiology, University of Maryland School of Medicine, Baltimore, Maryland,
12 USA

13 ⁵ Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
14 USA

15 ⁶ Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington,
16 Kentucky, USA

17 ⁷ Sanders-Brown Center on Aging University of Kentucky, Lexington, Kentucky, USA

18 **Corresponding Author:**

19 Brian T. Gold, PhD
20 Brian.Gold@uky.edu
21 MN 364 Medical Sciences Building
22 780 Rose Street
23 Lexington, KY 40536

24 **Total word count of manuscript: 5982**

25

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

1. Abstract

Background: Increasing evidence suggests that enlarged perivascular spaces (ePVS) are associated with cognitive dysfunction in aging. However, the etiology of ePVS remains unknown. Here we tested the possibility that baseline cerebrovascular dysfunction, as measured by an MRI measure of cerebrovascular reactivity (CVR), contributes to the later development of ePVS.

Methods: A total of 79 cognitively normal, older adults (46 women, age range 60-84) were recruited to undergo MRI scanning at baseline and 50 participants returned for a follow-up scan approximately 2.5 years later. ePVS were counted in the basal ganglia, centrum semiovale, midbrain, and hippocampus. CVR, an index of the vasodilatory capacity of cerebral small vessels, was assessed using carbon-dioxide inhalation while acquiring blood oxygen-level dependent (BOLD) MR images.

Results: Low baseline CVR values in the basal ganglia were associated with increased follow-up ePVS counts in the basal ganglia after controlling for age, sex, and baseline ePVS values (coefficient estimate (SE) = -15.87 (3.92), $p < 0.001$, 95% confidence interval [CI] -23.68 to -8.05). This effect remained significant after accounting for self-reported risk factors of cerebral small vessel disease (cSVD) (coefficient estimate (SE) = -15.03 (4.00), $p < 0.001$, CI -23.02 to -7.05) and neuroimaging markers of cSVD (coefficient estimate (SE) = -13.99 (4.02), $p < 0.001$, CI -22.03 to -5.95).

Conclusions: Our results demonstrate that low baseline CVR is a risk factor for later development of ePVS. MRI-based CVR may represent a promising biomarker of cSVD.

49

50

2. Introduction

51 Perivascular spaces (PVS) are pial-lined, fluid-filled spaces surrounding penetrating brain arteries

52 ¹. PVS are integral to neuroimmune function and clearance of metabolites via the brain's

53 glymphatic system as the site of interchange between interstitial fluid (ISF) and cerebrospinal fluid

54 (CSF) ^{2,3}. Enlarged perivascular spaces (ePVS) can be detected as dilated PVS on magnetic

55 resonance imaging (MRI). While originally considered a benign radiological finding, increasing

56 evidence suggests that ePVS may represent microvascular dysfunction and impaired ISF-CSF

57 interchange ^{1,4}.

58 Consistent with this possibility, a body of work has shown ePVS are associated with

59 cognitive dysfunction in aging ⁴⁻⁸. For example, we recently found that greater ePVS counts are

60 associated with lower scores on the Montreal Cognitive Assessment (MoCA), a standardized

61 clinical tool of global cognitive performance ⁸. In addition, two recent studies showed a

62 relationship between high ePVS burden and worse executive function performance ^{6,7}.

63 Despite such evidence supporting the clinical significance of ePVS, mechanistic

64 contributors to ePVS remain under-characterized. Functionally-based cerebrovascular dysfunction

65 could represent a contributing factor to structural PVS enlargement. For instance, reduced vascular

66 compliance could disrupt ISF-CSF interchange and impair waste clearance ^{4,9}. The reduced

67 clearance of brain waste could in turn promote PVS enlargement ³.

68 Testing this possibility requires a valid measure of cerebrovascular compliance. Recently,

69 a blood oxygen-level dependent (BOLD)-fMRI cerebrovascular reactivity (CVR) method has been

70 developed and validated as a measure of cerebrovascular compliance ¹⁰⁻¹². This CVR method

71 represents a functional assessment of the ability of the cerebrovascular system to dynamically

72 respond to a vasodilatory stimulus¹¹. Specifically, participants' cerebrovascular response to an in-
73 scanner hypercapnia challenge is measured by dividing the percent change in BOLD-fMRI signal
74 by the change in end-tidal CO₂ (mmHg) between normal room air breathing and hypercapnic air
75 breathing.

76 Importantly, several recent studies have described the cross-sectional association between
77 CVR and ePVS^{13,14}, further motivating a hypothesis that low baseline CVR may contribute to
78 later ePVS. Here, we tested this possibility in a longitudinal design involving a 2.5-year follow-
79 up sample of older adults who were cognitively normal at baseline. Since the basal ganglia is a
80 known predilection site of early cerebral small vessel disease (cSVD)^{15,16} that is closely associated
81 with cerebrovascular dysfunction¹⁷⁻¹⁹, we hypothesized that low baseline CVR in the basal ganglia
82 may predict increased ePVS counts in this region.

83 **3. Materials and Methods**

84 **3.1 Participants**

85 Eighty-one cognitively normal, older adults (age range 60-84, 46 women) were initially recruited
86 for this longitudinal experiment. Participants were recruited from an existing longitudinal cohort
87 at the Sanders-Brown Center on Aging (SBCoA) and the Lexington, KY community. Participants
88 were informed at the time of enrollment that this was a longitudinal study which involved baseline
89 MRI scanning and a follow-up MRI scan approximately 2.5 years later. All participants provided
90 informed written consent at each study time point under a protocol approved by the Institutional
91 Review Board of the University of Kentucky and this study is compliant with STROBE
92 (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines²⁰. Participants
93 were asked not to drink caffeine-based products on the day of their scan to minimize potential
94 confounding effects on CVR. All participants were cognitively unimpaired at baseline based on

95 either 1) clinical consensus diagnosis and scores from the Uniform Data Set (UDS3) used by US
96 ADCs (procedure outlined elsewhere ^{21,22}) or 2) a score of 26 or higher on the Montreal Cognitive
97 Assessment (MoCA) ²³ for those participants recruited from the community.

98 Exclusion criteria at each time point were significant head injury (defined as loss of
99 consciousness for more than 5 min), stroke, neurological disorders (e.g. epilepsy, Alzheimer's
100 disease) or major psychiatric disorders (e.g. schizophrenia, active clinical depression),
101 claustrophobia, pacemakers, the presence of metal fragments or implants that are incompatible
102 with MRI, or significant brain abnormalities detected during imaging. A board-certified
103 neuroradiologist (F.D.R.) evaluated the T1-weighted (T1W) and fluid-attenuated inversion
104 recovery (FLAIR) images for evidence of stroke or other clinically relevant abnormalities. This
105 resulted in exclusion of two participants due to evidence of previous stroke (one participant) and
106 hydrocephalus (one participant), not known at the time of enrollment. Participants were eligible
107 for rescan regardless of their cognitive status at the follow-up scan. Detailed characteristics of the
108 final group of 79 baseline participants and 50 follow-up participants are shown in Table 1.

109 [Insert Table 1 about here]

110 **3.2 Magnetic Resonance Imaging Protocol**

111 Participants were scanned in a Siemens 3T Prisma scanner (software version E11C), using a 64-
112 channel head coil, at the University of Kentucky's Magnetic Resonance Imaging and Spectroscopy
113 Center (MRISC). The following scans were acquired: (1) a 3D multi-echo, T1-weighted
114 magnetization prepared rapid gradient echo (ME-MPRAGE) scan, (2) a 3D fluid-attenuated
115 inversion recovery (FLAIR) scan, (3) a 3D, multi-echo gradient-recalled echo scan used for
116 quantitative susceptibility mapping (QSM), and (4) a BOLD EPI/fMRI scan for assessment of

117 cerebrovascular reactivity (CVR). Several other sequences were collected during the scanning
118 session related to other scientific questions and are not discussed further here.

119 The ME-MPRAGE sequence optimizes gray/white matter contrast²⁴ and covered the entire
120 brain [1 mm isotropic voxels, $256 \times 256 \times 176$ mm acquisition matrix, parallel imaging (GRAPPA)
121 acceleration = 2, repetition time (TR) = 2,530 millisecond (ms), inversion time = 1,100 ms, flip
122 angle (FA) = 7° , scan duration = 5.88 min] and had four echoes [first echo time (TE1) = 1.69 ms,
123 echo spacing (Δ TE = 1.86 ms)]. The 3D FLAIR sequence covered the entire brain (1 mm isotropic
124 voxels, $256 \times 256 \times 176$ acquisition matrix, TR = 5,000 ms, TE = 388 ms, inversion time = 1,800
125 ms, scan duration = 6.45 min). A high-resolution, flow compensated, multi-echo, 3D spoiled GRE
126 sequence with eight echoes (TR/TE1/ Δ TE/FA = 24ms/2.98ms/2.53ms/ 15°) was acquired and used
127 to create QSM images using Ironsmith, our in-house developed software described elsewhere²⁵.
128 The entire brain was covered [1.2 mm isotropic voxels, acquisition matrix = 224 x 224 x 144,
129 parallel imaging (GRAPPA) acceleration = 2, and scan duration = 6.18 min]. The CVR sequence
130 covered the entire brain [voxel size of $3.0 \times 3.0 \times 3.7$ mm³, acquisition matrix = $64 \times 64 \times 36$,
131 parallel imaging (GRAPPA) acceleration = 2, TR = 2,000 ms, TE = 30 ms, FA = 71° , number of
132 volumes = 216, and scan duration = 7.20 min].

133 **3.3 ePVS Counting**

134 We used a validated, visual rating method for quantification of region-specific ePVS burden
135 developed via collaboration between multiple consortia and intended to standardize ePVS
136 assessment across the field of cSVD research²⁶. As described in our previous work⁸, the method
137 involves manually counting ePVS on T1 images, with additional reference to T2 FLAIR images
138 and susceptibility weighted images. Counts were performed in each hemisphere on a single, axial
139 slice of T1 images, within four regions of interest (ROIs) that are known to have the greatest burden

140 of ePVS ^{5,15,16,26}: the centrum semiovale, 1 cm above the lateral ventricles; the basal ganglia, at
141 the level of the columns of the fornix, including the head of the caudate and the putamen (Figure
142 1); the midbrain, at the level of the cerebral peduncles; the hippocampus, at the level of the
143 midbrain.

144 [Insert Figure 1 about here]

145 Previous work by multiple consortia such as STandards for ReportIng Vascular changes
146 on nEuroimaging (STRIVE) and Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement
147 (UNIVRSE) have demonstrated the reliability of counting ePVS on T1, with very high correlation
148 to counts on T2 images ^{5,27,28} as well as a high correlation between single-slice and multi-slice
149 counts ^{26,28}. All baseline and follow-up counts were conducted by the lead author (T.J.L.), blinded
150 to participant demographics and neuropsychological scores, and under the supervision of an
151 experienced neuroradiologist (F.D.R.), who clarified unclear imaging features.

152 In accordance with STRIVE and UNIVRSE consensus guidelines ^{1,27,28}, ePVS were
153 identified using T1, FLAIR and susceptibility weighted images. Prior to counting, each
154 participant's T1 images were registered to their FLAIR and QSM images in native space. ePVS
155 were identified on T1 images as hypointense and less than 3mm in diameter to differentiate them
156 from lacunes, which tend to be larger ^{27,29}. ePVS were further differentiated from lacunes based
157 on their lack of hyperintensity on FLAIR ^{27,28}. ePVS were differentiated from cerebral microbleeds
158 (CMBs) by their absence of prominent associated blooming artifact on QSM. We used QSM for
159 differentiation of ePVS and CMBs due to evidence that QSM images outperform traditional single-
160 echo susceptibility weighted images in this regard ³⁰. Intra-rater reliability for ePVS was assessed
161 on a subset of 20 randomly selected participants, using intra-class correlation coefficients (ICC).

162 **3.4 Cerebrovascular Reactivity Imaging Procedure**

163 CVR was assessed using a previously described procedure^{10,12,31}. Briefly, participants were fitted
164 with a mouthpiece and nose-clip, and mild hypercapnic air (5% carbon dioxide, 74% nitrogen, and
165 21% oxygen) was administered using a Douglas bag, with a two-way non-rebreathing valve,
166 enabling precise switching between room-air and hypercapnic air³¹. Participants underwent
167 blocked inhalation of hypercapnic air and room air while blood oxygen level–dependent (BOLD)
168 MRIs were acquired continuously. A researcher was present inside the scanner room throughout
169 the experiment to manually switch the valve to control the breathing of air (either room air or
170 hypercapnic air from the Douglas bag). An interleaved, blocked fMRI design was used consisting
171 of 3 blocks (50 sec/block) of hypercapnic air, and 4 blocks (70 sec/block) of room air for a total
172 of 430 seconds. CO₂ concentration in the exhaled air was sampled at 100 Hz and the resulting CO₂
173 trace was recorded using capnography (Philips Respironics NM3 Monitor, Model 7900).

174 **3.5 CVR Data Processing**

175 CVR analysis was performed using a cloud-based online processing tool, CVR-MRICloud
176 (Version 5, <https://braingps.mricloud.org/cvr.v5>)^{32,33}. Briefly, the BOLD data were first motion
177 corrected and smoothed by an 8mm Gaussian kernel using SPM12. The end-tidal CO₂ (Et-CO₂)
178 was extracted from the CO₂ trace using an algorithm to identify the peak CO₂ of each exhaled
179 breath. The Et-CO₂ curve was then temporally aligned with the whole-brain averaged BOLD
180 signal time course. Whole-brain CVR values were subsequently obtained using a general linear
181 model (GLM) in which whole-brain averaged BOLD signal was the dependent variable and
182 temporally-aligned Et-CO₂ was the independent variable. The CVR values were scaled to units of
183 %BOLD signal change (in the CO₂-enhanced vs. normal air condition) per mm of mercury (Hg)
184 of Et-CO₂ change (%BOLD/mmHg CO₂).

185 Next, the BOLD images for individual participants were co-registered to the T1W ME-
186 MPRAGE [(the four echoes averaged into a root mean square (RMS)] image. The T1W images
187 were then segmented into ROIs by the T1 MultiAtlas Segmentation toolbox on MRICloud using
188 the “Adult50-90yrs_287Labels30atlases_M2_252_V10A” atlas. These atlas-derived ROI masks
189 were applied to the BOLD images to obtain ROI-averaged BOLD time courses, which were then
190 used in GLM analyses similar to the whole-brain CVR calculation to obtain regional CVR values
191 in specific ROIs (basal ganglia, hippocampus, and midbrain). An ROI mask of the centrum
192 semiovale, which is not included in the CVR-MRICloud toolbox atlas, was also created via an in-
193 house developed MATLAB script and FreeSurfer-based masks of the lateral ventricles.
194 Specifically, the centrum semiovale ROI was defined as the portion of a FreeSurfer-derived,
195 whole-brain white matter mask situated between two axial planes, relative to the lateral ventricles.
196 The superior plane of the ROI was 12mm above the superior margin of the lateral ventricles and
197 the inferior plane was 4mm above the superior margin of the lateral ventricles.

198 Lastly, CVR-MRICloud toolbox also provides the BOLD-CO₂ correlation coefficient as a
199 quality control measure. The BOLD-CO₂ correlation coefficient was used to compare the relative
200 coupling between BOLD signal and Et-CO₂ between our four ROIs to assess potential differences
201 in ROI signal quality.

202 **3.6 White Matter Hyperintensity Quantification**

203 Whole brain white matter hyperintensity (WMH) volumes were computed for use as a control
204 variable in our models testing if CVR predicts change in ePVS after controlling for neuroimaging
205 cSVD variables. Baseline total WMH volumes were computed using the UCD WMH segmentation
206 toolkit (Version 1.3), which employs a validated 4-tissue segmentation method³⁴. This pipeline
207 was chosen as it is also used for the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Briefly,

208 participants' ME-MPRAGE image [the four echoes averaged into a root mean square (RMS)
209 image] were first registered to their FLAIR image using FLIRT from FMRIB Software Library
210 version 6.0.1³⁵. The FLAIR image was then skull stripped, corrected for inhomogeneities using a
211 previously published local histogram normalization³⁶, and then non-linearly aligned to a standard
212 atlas³⁴. WMHs were estimated in standard space using Bayesian probability based on histogram
213 fitting and prior probability maps. Voxels labeled as WMHs based on these maps exceeded 3.5
214 SDs above the mean WM signal intensity. Manual editing was performed by labeling false positive
215 FLAIR hyperintensity as background. Total WMH volumes were calculated in participants' native
216 FLAIR space after back-transformation and reported in cubic millimeters.

217 **3.7 Statistical Analyses**

218 All statistical analyses were performed using SPSS (IBM, Armonk, NY, USA, version 28) with
219 results considered statistically significant at $p < 0.05$. Independent sample t-tests and paired sample
220 t-tests were used to examine differences between participants who were returners and non-
221 returners as well as baseline and follow-up measures, respectively. To test the impact of baseline
222 cerebrovascular dysfunction on longitudinal ePVS burden, a linear mixed effects model (restricted
223 maximum likelihood, identity covariance structure) with random intercepts was performed.
224 Specifically, the predictor variable was baseline CVR value in the basal ganglia and the dependent
225 variable was follow-up basal ganglia ePVS counts after controlling for baseline basal ganglia ePVS
226 counts. Time point was included as a factor in all models and additional covariates were age and
227 sex. Planned models using CVR in other ROIs as a predictor were not run due to relatively low
228 BOLD-CO₂ correlation coefficient (as described in the Results section).

229 For the ROI showing a significant relationship between baseline CVR and longitudinal
230 ePVS (i.e. the basal ganglia), two follow-up models were run to control for the potential influence

231 of other relevant cSVD factors. In the first follow-up model, available participant-reported cSVD
232 risk factors were added as covariates [body mass index (BMI), hypertension status, and type 2
233 diabetes status]. BMI was treated as a continuous variable and hypertension status and type 2
234 diabetes status were treated as dichotomous variables. In a second follow-up model, cSVD
235 neuroimaging measures were added as additional covariates [whole brain WMH volume, lacune
236 counts, and cerebral microbleed counts].

237 All predictors and dependent variables were tested for the assumption of normality using
238 the Shapiro-Wilk test. Collinearity between predictors in all models was explored using the
239 variance inflation factor (VIF), with a value of 5 implemented as a threshold value³⁷. Additionally,
240 continuous covariates were centered.

241 **3.8 Data Availability**

242 The raw data supporting the conclusions of this article will be made available by the authors,
243 without undue reservation.

244 **4. Results**

245 **4.1 Data Characteristics**

246 High intra-rater reliability was achieved for ePVS counts (ICC = 0.9) on a subset of 20
247 randomly selected participants. The mean follow-up time between the baseline and follow-up scan
248 was 2.56 years (SD = 0.16 years). A summary of mean baseline, follow-up, and change in ePVS
249 values in the 4 ROIs is presented in Table 2. Additionally, an illustrative case of ePVS progression
250 during the follow-up period is presented in Figure 2. Of the 79 participants that underwent baseline
251 MRI scanning, 50 returned for their follow-up MRI. This attrition rate is higher than is typical in
252 our previous longitudinal studies with this cohort and likely reflects, at least in part, concerns
253 related to participation in research during the COVID-19 pandemic. The use of linear mixed effects

254 models, which better handle missing data, allowed us to minimize data loss and maximize power
255 as compared to case-wise deletion methods. Returning participants were not significantly different
256 than non-returners in age at baseline ($t = 0.532$, $p = 0.596$), sex ($t = -1.093$, $p = 0.278$), or ePVS
257 counts in any of the four counting ROIs (All $p > 0.05$). However, returners had higher baseline
258 MoCA scores ($t = 2.148$, $p = 0.035$) and showed a trend toward having higher mean levels of
259 education ($t = 1.971$, $p = 0.052$) than non-returners. During the follow-up period, 7 of the 50
260 returner participants converted from cognitively normal to mild cognitive impairment based on
261 their MoCA scores (range = 22-25).

262 [Insert Figure 2 about here]

263 BOLD-CO₂ correlation coefficient, a quality control measure of CVR provided by the
264 CVR-MRICloud toolbox, was significantly higher in the basal ganglia than in the centrum
265 semiovale ($t = 73.3$, $p < 0.001$, Supplementary Table 1), midbrain ($t = 12.6$, $p < 0.001$,
266 Supplementary Table 1), and hippocampus ($t = 10.3$, $p < 0.001$, Supplementary Table 1). For this
267 reason, CVR values in the centrum semiovale, midbrain, and hippocampus were not included in
268 any additional analyses.

269 CVR values in the basal ganglia (W-statistic = 0.927; $p < 0.001$) as well as whole brain
270 WMHs (W-statistic = 0.581; $p < 0.001$) were skewed and therefore log-transformed. Variance
271 inflation factor for all predictors was < 2 and tolerance was > 0.5 in all analyses. Error residuals
272 from all ePVS analyses were normally distributed indicating that the assumption of normality was
273 met.

274 [Insert Table 2 about here]

275 **4.2 Relationship between Baseline CVR Values and Longitudinal ePVS Values**

276 All results for associations between baseline CVR and ePVS counts are reported in Table
277 3. Baseline log-transformed CVR values in the basal ganglia significantly predicted an increase in
278 basal ganglia ePVS counts over 2.5 years after controlling for baseline ePVS, age, and sex
279 (coefficient estimate (SE) = -15.87 (3.92), $p < 0.001$, 95% confidence interval [CI] -23.68 to -
280 8.05). Baseline CVR values in the basal ganglia did not significantly predict increased ePVS in
281 the centrum semiovale, hippocampus, or midbrain (Supplementary Table 2). To assess possible
282 lateralization effects, the relationships between left and right basal ganglia CVR values and
283 corresponding ePVS values were explored. Results indicated that lower baseline log-transformed
284 CVR values in the left basal ganglia significantly predicted increased ePVS values in the left basal
285 ganglia over time (coefficient estimate (SE) = -7.62 (4.78), $p < 0.001$, 95% CI -11.85 to -3.38).
286 Similarly, lower baseline log-transformed CVR values in the right basal ganglia significantly
287 predicted increased ePVS values in the right basal ganglia over time (coefficient estimate (SE) = -
288 7.91 (2.15), $p < 0.001$, 95% CI -12.19 to -3.62).

289 Two additional models were conducted to determine the impact of including additional
290 cSVD covariates on the significance of the CVR-ePVS basal ganglia models. Model 2 accounted
291 for participant-reported cSVD risk factors including hypertension status, type 2 diabetes status,
292 and body mass index (BMI). In addition to the cSVD risk factors in Model 2, Model 3 further
293 accounted for several known cSVD neuroimaging markers: lacunes, CMBs, and log-transformed
294 whole brain WMH volume. Results indicated that CVR remained a significant predictor of
295 increased ePVS counts in the basal ganglia over time after controlling for participant-reported
296 cSVD risk factors (Model 2; Table 3) and additional cSVD neuroimaging markers (Model 3; Table
297 3). In addition, when testing potential lateralization effects, the relationships between individual
298 left and right basal ganglia CVR values and corresponding longitudinal basal ganglia ePVS values

299 remained significant after accounting for both participant-reported cSVD risk factors (Model 2)
300 and additional cSVD neuroimaging marker covariates (Model 3).

301 [Insert Table 3 about here]

302 **5. Discussion**

303 We tested whether baseline cerebrovascular reactivity (CVR) contributes to the later development
304 of enlarged perivascular spaces (ePVS) in community-dwelling older adults. Our results showed
305 that lower CVR values in the basal ganglia at baseline predicted a longitudinal increase in ePVS
306 counts in the basal ganglia over a 2.5-year follow-up period. This finding supports a view that
307 cerebrovascular dysfunction contributes to the development of ePVS in the basal ganglia.

308 Importantly, the relationship we observed between CVR and ePVS could not be accounted
309 for by other commonly studied markers of cSVD. Specifically, the relationship between CVR and
310 ePVS in the basal ganglia remained significant after controlling for the participant-reported cSVD
311 risk factors of hypertension status, type 2 diabetes status and BMI (Model 2). In addition, the
312 longitudinal relationship between CVR and ePVS in the basal ganglia remained significant after
313 controlling for commonly used neuroimaging markers of cSVD including WMH volume, lacune
314 count, and cerebral microbleed count (Model 3). Together, these results indicate that
315 cerebrovascular compliance in the basal ganglia, as measured by BOLD-CVR, contributes to the
316 subsequent development of ePVS in the basal ganglia.

317 One pathway through which reduced cerebrovascular compliance may lead to increased
318 ePVS burden relates to glymphatic waste removal. The functional measure of cerebrovascular
319 reactivity (BOLD-CVR) is an indicator of cerebrovascular compliance and reserve capacity^{11,38}.
320 Diminished cerebrovascular compliance and reduced reserve capacity may impair vasomotion and
321 pulsatility, which are required for effective glymphatic waste elimination^{3,9,39}. Reduced

322 glymphatic waste removal may in turn lead to accumulation within the PVS and increased ePVS
323 burden³.

324 While our findings are novel, they are consistent with results from several studies that
325 reported a relationship between non-neuroimaging measures of cerebrovascular dysfunction and
326 PVS enlargement in the basal ganglia. For instance, basal ganglia ePVS are independently related
327 to non-imaging measures of arterial stiffness^{17,18}, hypertensive arteriopathy^{19,40}, and
328 atherosclerosis⁴¹. Localization of such findings to the basal ganglia may be in part a result of an
329 increased susceptibility to the early effects of cSVD in the perforating arterioles that supply the
330 basal ganglia^{4,42}.

331 Our results further suggest that rates of ePVS accumulation may differ as a function of brain
332 region. In our sample, a significant longitudinal increase in ePVS burden was observed in 3 brain
333 regions (the basal ganglia, centrum semiovale, and midbrain). In contrast, the hippocampus
334 showed the lowest rate of increase (7.9%), which was not significant in our sample. Future research
335 with larger sample sizes will be needed to establish normative data on ePVS accumulation in
336 different brain regions, the results of which will be of importance to the planning of future clinical
337 trials that use ePVS as an outcome measure.

338 The main limitation of our study is that BOLD-fMRI is less sensitive in ROIs associated
339 with fewer blood vessels. This resulted in comparably lower BOLD-CO₂ correlation coefficient
340 (quality control) values in the centrum semiovale, midbrain, and hippocampus, which prevented
341 us from performing formal analyses in these ROIs. Furthermore, the relationship between BOLD
342 signal and CO₂ partial pressure may not be linear⁴³. As other human biomarker studies, our
343 methods do not allow for conclusions about direct mechanisms. Future research using animal
344 models will be required to delineate the mechanistic pathways through which poor vascular

345 compliance contributes to ePVS development. An additional limitation to our study is our cohort
346 included primarily highly educated, primarily White participants. Our findings will need to be
347 replicated in more ethnically and demographically diverse cohorts.

348 *Conclusions*

349 Our results indicate that cerebrovascular dysfunction is a contributing factor to ePVS
350 accumulation in the basal ganglia. Future work should explore additional contributors to ePVS
351 accumulation including the overproduction of proteins associated with neurodegeneration,
352 including β -amyloid and tau. A better understanding of the mechanistic contributors to ePVS
353 accumulation could point to early intervention targets intended to slow or prevent the symptoms
354 associated with cSVD.

355 **Funding**

356 This work was supported by the National Institutes of Health [grant numbers NIA P30 AG072946
357 (Brian T. Gold), NIA P30 AG028383 - 15S1 (Brian T. Gold), NIA R01 AG055449 (Brian T.
358 Gold), NIA R01 AG068055 (Brian T. Gold), NINDS RF1 NS122028 (Brian T. Gold), NIBIB P41
359 EB031771 (Hanzhang Lu), NIA F30 AG079506-01A1 (T.J. Libecap)]. T.J. Libecap was also
360 supported by an award from the American Heart Association (AHA 903649). The content is solely
361 the responsibility of the authors and does not necessarily represent the official views of these
362 granting agencies.

363 **Acknowledgments**

364 We thank the dedicated research volunteers that make this work possible. We also thank Beverly
365 Meacham, Eric Forman, Beatriz Rodolpho, and Stephen Dundon for assistance with MRI
366 scanning, and Dr. David Powell for assistance with pulse sequence programming and selection.
367 The authors declare no competing financial interests.

368

References

- 369 1. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain:
370 anatomy, physiology and pathology. *Nat Rev Neurol*. 2020;16(3):137-153.
371 doi:10.1038/s41582-020-0312-z
- 372 2. Iliff JJ, Wang M, Liao Y, et al. A Paravascular Pathway Facilitates CSF Flow Through the
373 Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β . *Sci*
374 *Transl Med*. 2012;4(147). doi:10.1126/scitranslmed.3003748
- 375 3. Kylkilahti TM, Berends E, Ramos M, et al. Achieving brain clearance and preventing
376 neurodegenerative diseases—A glymphatic perspective. *Journal of Cerebral Blood Flow*
377 *and Metabolism*. 2021;41(9):2137-2149. doi:10.1177/0271678X20982388
- 378 4. Bown CW, Carare RO, Schrag MS, Jefferson AL. Physiology and Clinical Relevance of
379 Enlarged Perivascular Spaces in the Aging Brain. *Neurology*. 2022;98(3):107-117.
380 doi:10.1212/WNL.00000000000013077
- 381 5. Hilal S, Tan CS, Adams HHH, et al. Enlarged perivascular spaces and cognition.
382 *Neurology*. 2018;91(9):e832-e842. doi:10.1212/WNL.0000000000006079
- 383 6. Passiak BS, Liu D, Kresge HA, et al. Perivascular spaces contribute to cognition beyond
384 other small vessel disease markers. *Neurology*. 2019;92(12):e1309-e1321.
385 doi:10.1212/WNL.00000000000007124
- 386 7. Choe YM, Baek H, Choi HJ, et al. Association Between Enlarged Perivascular Spaces and
387 Cognition in a Memory Clinic Population. *Neurology*. 2022;99(13):E1414-E1421.
388 doi:10.1212/WNL.00000000000200910
- 389 8. Libecap TJ, Zachariou V, Bauer CE, et al. Enlarged Perivascular Spaces Are Negatively
390 Associated With Montreal Cognitive Assessment Scores in Older Adults. *Front Neurol*.
391 2022;13. doi:10.3389/fneur.2022.888511
- 392 9. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular
393 CSF-Interstitial fluid exchange in the murine brain. *Journal of Neuroscience*.
394 2013;33(46):18190-18199. doi:10.1523/JNEUROSCI.1592-13.2013
- 395 10. Lu H, Liu P, Yezhuvath U, Cheng Y, Marshall O, Ge Y. MRI mapping of cerebrovascular
396 reactivity via gas inhalation challenges. *Journal of Visualized Experiments*. 2014;(94).
397 doi:10.3791/52306
- 398 11. Liu P, de Vis JB, Lu H. Cerebrovascular reactivity (CVR) MRI with CO₂ challenge: A
399 technical review. *Neuroimage*. 2019;187:104-115. doi:10.1016/j.neuroimage.2018.03.047
- 400 12. Liu P, Jiang D, Albert M, et al. Multi-vendor and multisite evaluation of cerebrovascular
401 reactivity mapping using hypercapnia challenge. *Neuroimage*. 2021;245.
402 doi:10.1016/j.neuroimage.2021.118754
- 403 13. Blair GW, Thrippleton MJ, Shi Y, et al. Intracranial hemodynamic relationships in
404 patients with cerebral small vessel disease. *Neurology*. 2020;94(21):e2258-e2269.
405 doi:10.1212/WNL.00000000000009483
- 406 14. Kapoor A, Yew B, Jang JY, et al. Older adults with perivascular spaces exhibit
407 cerebrovascular reactivity deficits. *Neuroimage*. Published online November
408 2022;119746. doi:10.1016/j.neuroimage.2022.119746
- 409 15. Rouhl RPW, van Oostenbrugge RJ, Knottnerus ILH, Staals JEA, Lodder J. Virchow-
410 Robin spaces relate to cerebral small vessel disease severity. *J Neurol*. 2008;255(5):692-
411 696. doi:10.1007/s00415-008-0777-y

- 412 16. Doubal FN, MacLulich AMJ, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged
413 Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel Disease. *Stroke*.
414 2010;41(3):450-454. doi:10.1161/STROKEAHA.109.564914
- 415 17. Bae JH, Kim JM, Park KY, Han SH. Association between arterial stiffness and the
416 presence of cerebral small vessel disease markers. *Brain Behav*. 2021;11(1).
417 doi:10.1002/brb3.1935
- 418 18. Riba-Llena I, Jiménez-Balado J, Castañé X, et al. Arterial Stiffness Is Associated With
419 Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load.
420 *Stroke*. 2018;49(5):1279-1281. doi:10.1161/STROKEAHA.118.020163
- 421 19. van den Kerkhof M, van der Thiel MM, van Oostenbrugge RJ, et al. Impaired damping of
422 cerebral blood flow velocity pulsatility is associated with the number of perivascular
423 spaces as measured with 7T MRI. *Journal of Cerebral Blood Flow & Metabolism*.
424 Published online January 26, 2023:0271678X2311533. doi:10.1177/0271678X231153374
- 425 20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
426 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
427 statement: guidelines for reporting observational studies. *J Clin Epidemiol*.
428 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
- 429 21. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and
430 Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. *Alzheimer*
431 *Dis Assoc Disord*. 2006;20(4):210-216. doi:10.1097/01.wad.0000213865.09806.92
- 432 22. Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer's
433 Coordinating Center's Uniform Data Set. *Alzheimer Dis Assoc Disord*. 2018;32(4):351-
434 358. doi:10.1097/WAD.0000000000000279
- 435 23. Nasreddine ZS, Phillips NA, Bäckström V, et al. The Montreal Cognitive Assessment,
436 MoCA: A Brief Screening Tool For Mild Cognitive Impairment. *J Am Geriatr Soc*.
437 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x
- 438 24. van der Kouwe AJW, Benner T, Salat DH, Fischl B. Brain morphometry with multiecho
439 MPRAGE. *Neuroimage*. 2008;40(2):559-569. doi:10.1016/j.neuroimage.2007.12.025
- 440 25. Zachariou V, Bauer CE, Powell DK, Gold BT. Ironsmith: An automated pipeline for
441 QSM-based data analyses. *Neuroimage*. 2022;249.
442 doi:10.1016/j.neuroimage.2021.118835
- 443 26. Adams HHH, Cavalieri M, Verhaaren BFJ, et al. Rating Method for Dilated Virchow-
444 Robin Spaces on Magnetic Resonance Imaging. *Stroke*. 2013;44(6):1732-1735.
445 doi:10.1161/STROKEAHA.111.000620
- 446 27. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into
447 small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*.
448 2013;12(8):822-838. doi:10.1016/S1474-4422(13)70124-8
- 449 28. Adams HHH, Hilal S, Schwingsenschuh P, et al. A priori collaboration in population
450 imaging: The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement
451 consortium. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*.
452 2015;1(4):513-520. doi:10.1016/j.dadm.2015.10.004
- 453 29. Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction from
454 enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. *J*
455 *Neurol*. 1998;245(2):116-122. doi:10.1007/s004150050189

- 456 30. Liu T, Surapaneni K, Lou M, Cheng L, Spincemaille P, Wang Y. Cerebral Microbleeds:
457 Burden Assessment by Using Quantitative Susceptibility Mapping. *Radiology*.
458 2012;262(1):269-278. doi:10.1148/radiol.11110251
- 459 31. Lu H, Kashani AH, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II.
460 Neuroimaging protocols. *Alzheimer's and Dementia*. 2021;17(4):716-725.
461 doi:10.1002/alz.12216
- 462 32. Mori S, Wu D, Ceritoglu C, et al. MRICloud: Delivering High-Throughput MRI
463 Neuroinformatics as Cloud-Based Software as a Service. *Comput Sci Eng*. 2016;18(5):21-
464 35. doi:10.1109/MCSE.2016.93
- 465 33. Liu P, Baker Z, Li Y, et al. CVR-MRICloud: An online processing tool for CO2-
466 inhalation and resting-state cerebrovascular reactivity (CVR) MRI data. *PLoS One*.
467 2022;17(9):e0274220. doi:10.1371/journal.pone.0274220
- 468 34. DeCarli C, Maillard P, Fletcher E. Four Tissue Segmentation in ADNI II. Alzheimer's
469 Disease Neuroimaging Initiative (2013). Available online at:
470 https://files.alz.washington.edu/documentation/adni_proto.pdf (accessed March 1, 2022)
- 471 35. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. *Neuroimage*.
472 2012;62(2):782-790. doi:10.1016/j.neuroimage.2011.09.015
- 473 36. Decarli C, Murphy DGM, Teichberg D, Campbell G, Sobering GS. Local histogram
474 correction of MRI spatially dependent image pixel intensity nonuniformity. *Journal of*
475 *Magnetic Resonance Imaging*. 1996;6(3):519-528. doi:10.1002/jmri.1880060316
- 476 37. Stine RA. Graphical Interpretation of Variance Inflation Factors. *Am Stat*. 1995;49(1):53-
477 56. doi:10.1080/00031305.1995.10476113
- 478 38. Juttukonda MR, Donahue MJ. Neuroimaging of vascular reserve in patients with
479 cerebrovascular diseases. *Neuroimage*. 2019;187:192-208.
480 doi:10.1016/j.neuroimage.2017.10.015
- 481 39. van Veluw SJ, Hou SS, Calvo-Rodriguez M, et al. Vasomotion as a Driving Force for
482 Paravascular Clearance in the Awake Mouse Brain. *Neuron*. 2020;105(3):549-561.e5.
483 doi:10.1016/j.neuron.2019.10.033
- 484 40. Charidimou A, Boulouis G, Pasi M, et al. *MRI-Visible Perivascular Spaces in Cerebral*
485 *Amyloid Angiopathy and Hypertensive Arteriopathy*.; 2017.
- 486 41. Du H, Chen C, Ye C, et al. Association Between Steno-Occlusive Middle Cerebral Artery
487 and Basal Ganglia Perivascular Spaces. *Front Neurol*. 2020;11.
488 doi:10.3389/fneur.2020.00293
- 489 42. Rivera-Rivera LA, Schubert T, Turski P, et al. Changes in intracranial venous blood flow
490 and pulsatility in Alzheimer's disease: A 4D flow MRI study. *Journal of Cerebral Blood*
491 *Flow & Metabolism*. 2017;37(6):2149-2158. doi:10.1177/0271678X16661340
- 492 43. Hou X, Liu P, Li Y, et al. The association between BOLD-based cerebrovascular
493 reactivity (CVR) and end-tidal CO2 in healthy subjects. *Neuroimage*. 2020;207.
494 doi:10.1016/j.neuroimage.2019.116365
- 495
496
497
498
499
500
501

Table 1

Demographics and Mean Cognitive Measures

	Baseline	Follow-up
N	79	50
Sex (F:M)	46:33	31:19
Age Range (years)	60-84	62-86
Age (years)	69.81 (5.34)	72.6 (5.77)
Education (years)	16.42 (2.48)	16.82 (2.49)
Time Between Scans (years)	-	2.557 (0.158)
MoCA	26.62 (2.55)	26.33 (2.40)
BMI	28.14 (6.17)	27.85 (6.28)
Hypertension, N (%)	34 (43.0)	20 (40.0)
Type 2 Diabetes, N (%)	9 (11.4)	5 (10.0)
Lacunae, N (%)	25 (31.6)	27 (54)
Cerebral microbleeds, N (%)	35 (44.3)	33 (66)

502 The table lists the mean (\pm sd) for age, the female to male ratio, years of education, time between
503 baseline and follow-up scan, MoCA scores, and BMI. The number and percentage, N (%), of
504 participants positive for additional self-reported vascular risk factors and cSVD neuroimaging
505 markers are also reported. Baseline MoCA scores were unavailable for 2 participants.
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521

Table 2

Summary of ePVS values in the 4 ROIs at baseline and follow-up

ePVS ROI	Baseline Count (N = 79)	Follow-up Count (N = 50)	Mean Increase (N = 50)	% Increase	t- statistic	Two-sided p-value
Basal ganglia	17.90 (4.54)	21.32 (4.86)	4.02 (2.73)	23.2	10.415	< 0.001***
Centrum semiovale	52.13 (16.98)	54.34 (15.15)	4.88 (5.40)	9.9	6.394	< 0.001***
Midbrain	3.81 (2.67)	4.72 (2.49)	1.22 (2.10)	34.9	4.103	< 0.001***
Hippocampus	5.70 (2.79)	5.98 (2.58)	0.44 (2.49)	7.9	1.248	0.218

522 This table lists the mean baseline (\pm sd), follow-up (\pm sd) and change (\pm sd) in ePVS across time
523 points. Paired t-tests show ePVS significantly increased in the basal ganglia, centrum semiovale
524 and midbrain, but not in the hippocampus.

525 *** $p \leq 0.001$

526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550

Table 3

Mixed effects model: relationship between log-transformed baseline CVR and longitudinal ePVS

ROI	Model 1	Model 2	Model 3
Basal Ganglia	-15.87 (3.92), p < 0.001***, CI: -23.68 to -8.05	-15.03 (4.00), p < 0.001***, CI: -23.02 to -7.05	-13.99 (4.03), p = 0.001***, CI: -22.03 to -5.95
Left Basal Ganglia	-7.62 (2.13), p < 0.001***, CI: -11.85 to -3.38	-7.32 (2.16), p < 0.001***, CI: -11.62 to -3.01	-6.62 (2.11), p = 0.003**, CI: -10.84 to -2.40
Right Basal Ganglia	-7.91 (2.15), p < 0.001***, CI: -12.19 to -3.62	-7.47 (2.20), p = 0.001***, CI: -11.86 to -3.08	-7.23 (2.22), p = 0.002**, CI: -11.66 to -2.79

551 Values are measure coefficient estimate (SE), p value, 95% Confidence Interval. ePVS, enlarged
 552 perivascular spaces; BG, basal ganglia.

553 Model 1: adjusted for age, sex, and time point.

554 Model 2: adjusted for covariates in Model 1 and participant-reported hypertension status, type 2
 555 diabetes status, and BMI

556 Model 3: adjusted for covariates in Model 2 and lacunes, cerebral microbleeds, and log-
 557 transformed whole brain WMH

558 *p < 0.05

559 **p ≤ 0.01

560 ***p ≤ 0.001

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579 **Figure 1:** Example of basal ganglia ePVS on a T1-weighted image. An axial slice from
580 representative participant is shown in the plane of the columns of the fornix. ePVS were counted
581 within the head of the caudate (yellow arrow) and putamen (green arrow). A high intra-rater
582 reliability (ICC = 0.9) was achieved for ePVS on a subset of 20 randomly selected participants.

583



584

585

586

587

588

589

590

591

592

593

594

595

596

597

598 **Figure 2:** Example of basal ganglia ePVS burden at baseline and follow-up scan in a representative
599 participant. Inset shows high ePVS burden and red arrows indicate several ePVS that developed
600 during the follow-up period.

601

